SCHEMBL6334017

SCHEMBL6334017

O=CC(=C\c1ccccc1OCc1ccccc1)/C(C=O)=C/c1ccccc1OCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 1/20 0.62
CDK1 P06493 1/20 0.62
CDK4 P11802 1/20 0.62
CCNB1 P14635 1/20 0.62
CCND1 P24385 1/20 0.62
CCNB3 Q8WWL7 1/20 0.62
PTGER1 P34995 1/20 0.56
PTGER4 P35408 1/20 0.56
PTGER3 P43115 1/20 0.56
PTGER2 P43116 1/20 0.56
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 3/20 0.49
LMNA P02545 3/20 0.49
HPGD P15428 1/20 0.49
RECQL P46063 1/20 0.49
KMT2A Q03164 4/20 0.49
MAPT P10636 4/20 0.49
MEN1 O00255 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
NPC1 O15118 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6334019 1.00 CCNB2 (0.62) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL6331852 0.88 PTP4A3 (0.49) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL6331941 0.88 MAPT (0.66) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL6331850 0.88 PTP4A3 (0.49) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL6331944 0.88 MAPT (0.66) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL6334067 0.83 MAPT (0.71) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL6334069 0.83 MAPT (0.71) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL433401 0.81 CCNB2 (0.72) CCNB2CDK1CDK4CCNB1CCND1
SCHEMBL29537861 0.81 CCNB2 (0.72) CCNB2CDK1CDK4CCNB1CCND1
Fluoride SCHEMBL27920182 0.80 CCNB2 (0.70) CCNB2CDK1CDK4CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949682-B2 Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-09-27 US claimed
US-6949682-B2 Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-09-27 US disclosed
US-20040254196-A1 Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254196-A1 Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof CCNI, CDC25C, CDC25B CCNB2 12/4885CDK1 31/4885CDK4 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.